-
Product Insights
NewNet Present Value Model: UroGen Pharma Ltd’s Vesigel
Empower your strategies with our Net Present Value Model: UroGen Pharma Ltd's Vesigel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Gastroesophageal (GE) Junction Carcinomas Drug Details: CX-072...
-
Innovation Ranking
Innovation Ranking – UroGen Pharma Ltd
UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd, is a biopharmaceutical company that develops novel medicines to treat cancer indications and urologic diseases. The company products include Jelmyto is a drug formulation of mitomycin used to treat low-grade upper tract urothelial cancer. Its pipeline products include UGN-102 is a mitomycin gel is used to treat low-grade intermediate risk non-muscle invasive bladder cancer; UGN-201 and UGN-302 targets high-grade non-muscle invasive bladder cancer and Botox or RTgel for the treatment of overactive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imiquimod + Zalifrelimab in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imiquimod + Zalifrelimab in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imiquimod + Zalifrelimab in Prostate Cancer Drug Details: UGN-302, a...
-
Product Insights
NewNon Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024
Empower your strategies with our Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-5305 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-5305 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-5305 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iodine I 131 Apamistamab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vesigel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vesigel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vesigel in Non Muscle Invasive Bladder...
-
Company Insights
Innovation and Patenting activity of UroGen Pharma Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of UroGen Pharma Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
UroGen Pharma Ltd – Company Profile
UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd, is a biopharmaceutical company that develops novel medicines to treat cancer indications and urologic diseases. It is headquartered in Ra'Anana, Israel.
Add to Basket